Europe Nasal Spray Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Europe nasal spray market is projected to register a CAGR of 6.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Europe Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe nasal spray market are:

Rise in the therapeutic application of the nasal spray

Increase in the demand for nasal sprays for allergic diseases and pandemics such as COVID-19

Market Players

Some of the major market players operating in the Europe nasal spray market are:

EMERGENT

Cipla Inc.

Sandoz International GmbH (A Part of Novartis)

Aytu Health (A subsidiary of Aytu BioPharma, Inc.)

Bayer AG

GlaxoSmithKline plc.

Assertio Therapeutics, Inc.

Aurena Laboratories.

J Pharmaceuticals

St. Renatus.

Ultratech India Limited

Catalent, Inc.

Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd)

Pfizer Inc.

Viatris Inc.

LEEFORD HEALTHCARE LTD

Aishwarya Group

1 INTRODUCTION 23

1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25

2 MARKET SEGMENTATION 27

2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCT TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38

3 EXECUTIVE SUMMARY 39

4 PREMIUM INSIGHTS 42

4.1 PORTER'S FIVE FORCES MODEL 45
4.2 PESTEL ANALYSIS 46

5 INDUSTRY INSIGHTS: EUROPE NASAL SPRAY MARKET 47

5.1 INDUSTRY INSIGHTS 47

6 REGULATIONS: EUROPE NASAL SPRAY MARKET 48

6.1 REGULATORY SCENARIO IN EUROPE 48

7 MARKET OVERVIEW 49

7.1 DRIVERS 51
- 7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 51
- 7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 51
- 7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 52
- 7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 53
7.2 RESTRAINTS 54
- 7.2.1 PRODUCT RECALLS 54
- 7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 55
7.3 OPPORTUNITIES 56
- 7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 56
- 7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 56
- 7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 57
7.4 CHALLENGES 57
- 7.4.1 REGULATORY HURDLES 57
- 7.4.2 ADDICTION TO NASAL SPRAY 58

8 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE 59

8.1 OVERVIEW 60
8.2 DECONGESTION NASAL SPRAY 63
8.3 STEROID NASAL SPRAY 64
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 65
8.5 OTHERS 66

9 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN 67

9.1 OVERVIEW 68
9.2 PUMP BOTTLES 71
9.3 PRESSURIZED CANISTERS 72

10 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM 73

10.1 OVERVIEW 74
10.2 MULTI DOSE 77
10.3 UNIT/SINGLE DOSE 78
10.4 BI DOSE 79

11 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 81

11.1 OVERVIEW 82
11.2 ANTIHISTAMINE 85
11.3 NASAL STEROIDS 86
11.4 MAST CELL INHIBITOR 87
11.5 ANTICHOLINERGIC 88

12 EUROPE NASAL SPRAY MARKET, BY APPLICATION 89

12.1 OVERVIEW 90
12.2 NASAL CONGESTION 93
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 94
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 95
12.5 VACCINATION 96
12.6 OTHERS 97

13 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 98

13.1 OVERVIEW 99
13.2 PRESCRIBED 102
13.3 OVER THE COUNTER 103

14 EUROPE NASAL SPRAY MARKET, BY END USER 105

14.1 OVERVIEW 106
14.2 HOME CARE SETTINGS 109
14.3 HOSPITALS 110
14.4 CLINICS 111
14.5 COMMUNITY HEALTH CARE 112

15 EUROPE NASAL SPRAY MARKET, BY REGION 113

15.1 EUROPE 114
- 15.1.1 GERMANY 122
- 15.1.2 U.K. 124
- 15.1.3 FRANCE 126
- 15.1.4 ITALY 128
- 15.1.5 SPAIN 130
- 15.1.6 SWITZERLAND 132
- 15.1.7 NETHERLANDS 134
- 15.1.8 BELGIUM 136
- 15.1.9 RUSSIA 138
- 15.1.10 TURKEY 140
- 15.1.11 REST OF EUROPE 142

16 EUROPE NASAL SPRAY MARKET, COMPANY LANDSCAPE 143

16.1 COMPANY SHARE ANALYSIS: EUROPE 143

17 SWOT ANALYSIS 144

18 COMPANY PROFILE 145

18.1 GLAXOSMITHKLINE PLC. 145
- 18.1.1 COMPANY SNAPSHOT 145
- 18.1.2 REVENUE ANALYSIS 145
- 18.1.3 COMPANY SHARE ANALYSIS 146
- 18.1.4 PRODUCT PORTFOLIO 146
- 18.1.5 RECENT DEVELOPMENTS 146
18.2 PFIZER INC. 148
- 18.2.1 COMPANY SNAPSHOT 148
- 18.2.2 REVENUE ANALYSIS 148
- 18.2.3 COMPANY SHARE ANALYSIS 149
- 18.2.4 PRODUCT PORTFOLIO 149
- 18.2.5 RECENT DEVELOPMENTS 149
18.3 EMERGENT 151
- 18.3.1 COMPANY SNAPSHOT 151
- 18.3.2 REVENUE ANALYSIS 151
- 18.3.3 COMPANY SHARE ANALYSIS 152
- 18.3.4 PRODUCT PORTFOLIO 152
- 18.3.5 RECENT DEVELOPMENT 152
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 153
- 18.4.1 COMPANY SNAPSHOT 153
- 18.4.2 REVENUE ANALYSIS 153
- 18.4.3 COMPANY SHARE ANALYSIS 154
- 18.4.4 PRODUCT PORTFOLIO 154
- 18.4.5 RECENT DEVELOPMENT 154
18.5 CATALENT, INC. 155
- 18.5.1 COMPANY SNAPSHOT 155
- 18.5.2 REVENUE ANALYSIS 155
- 18.5.3 COMPANY SHARE ANALYSIS 156
- 18.5.4 PRODUCT PORTFOLIO 156
- 18.5.5 RECENT DEVELOPMENTS 156
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 158
- 18.6.1 COMPANY SNAPSHOT 158
- 18.6.2 REVENUE ANALYSIS 158
- 18.6.3 PRODUCT PORTFOLIO 159
- 18.6.4 RECENT DEVELOPMENTS 159
18.7 AISHWARYA GROUP 160
- 18.7.1 COMPANY SNAPSHOT 160
- 18.7.2 PRODUCT PORTFOLIO 160
- 18.7.3 RECENT DEVELOPMENTS 160
18.8 ASSERTIO THERAPEUTICS, INC. 161
- 18.8.1 COMPANY SNAPSHOT 161
- 18.8.2 REVENUE ANALYSIS 161
- 18.8.3 PRODUCT PORTFOLIO 162
- 18.8.4 RECENT DEVELOPMENT 162
18.9 AURENA LABORATORIES. 163
- 18.9.1 COMPANY SNAPSHOT 163
- 18.9.2 PRODUCT PORTFOLIO 163
- 18.9.3 RECENT DEVELOPMENTS 163
18.10 BAYER AG 165
- 18.10.1 COMPANY SNAPSHOT 165
- 18.10.2 REVENUE ANALYSIS 165
- 18.10.3 COMPANY SHARE ANALYSIS 166
- 18.10.4 PRODUCT PORTFOLIO 166
- 18.10.5 RECENT DEVELOPMENTS 166
18.11 CIPLA INC. 168
- 18.11.1 COMPANY SNAPSHOT 168
- 18.11.2 REVENUE ANALYSIS 168
- 18.11.3 PRODUCT PORTFOLIO 169
- 18.11.4 RECENT DEVELOPMENT 169
18.12 J PHARMACEUTICALS. 170
- 18.12.1 COMPANY SNAPSHOT 170
- 18.12.2 PRODUCT PORTFOLIO 170
- 18.12.3 RECENT DEVELOPMENTS 170
18.13 LEEFORD HEALTHCARE LTD 171
- 18.13.1 COMPANY SNAPSHOT 171
- 18.13.2 PRODUCT PORTFOLIO 171
- 18.13.3 RECENT DEVELOPMENTS 171
18.14 ST. RENATUS. 172
- 18.14.1 COMPANY SNAPSHOT 172
- 18.14.2 PRODUCT PORTFOLIO 172
- 18.14.3 RECENT DEVELOPMENTS 172
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 173
- 18.15.1 COMPANY SNAPSHOT 173
- 18.15.2 REVENUE ANALYSIS 173
- 18.15.3 PRODUCT PORTFOLIO 174
- 18.15.4 RECENT DEVELOPMENTS 174
18.16 ULTRATECH INDIA LIMITED 175
- 18.16.1 COMPANY SNAPSHOT 175
- 18.16.2 PRODUCT PORTFOLIO 175
- 18.16.3 RECENT DEVELOPMENTS 175
18.17 VIATRIS INC. 176
- 18.17.1 COMPANY SNAPSHOT 176
- 18.17.2 REVENUE ANALYSIS 176
- 18.17.3 COMPANY SHARE ANALYSIS 177
- 18.17.4 PRODUCT PORTFOLIO 177
- 18.17.5 RECENT DEVELOPMENT 177

19 QUESTIONNAIRE 178

20 RELATED REPORTS 182

LIST OF TABLES

TABLE 1 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 56
TABLE 2 EUROPE DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 3 EUROPE STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 4 EUROPE SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 5 EUROPE OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 6 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 64
TABLE 7 EUROPE PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 8 EUROPE PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 9 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 70
TABLE 10 EUROPE MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 11 EUROPE UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 12 EUROPE BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 13 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 78
TABLE 14 EUROPE ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 15 EUROPE NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 16 EUROPE MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 17 EUROPE ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 18 EUROPE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 86
TABLE 19 EUROPE NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 20 EUROPE ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 21 EUROPE CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 22 EUROPE VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 23 EUROPE OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 24 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 95
TABLE 25 EUROPE PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 26 EUROPE OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 27 EUROPE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 102
TABLE 28 EUROPE HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 29 EUROPE HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 30 EUROPE CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 31 EUROPE COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 32 EUROPE NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 113
TABLE 33 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113
TABLE 34 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 113
TABLE 35 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 114
TABLE 36 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 114
TABLE 37 EUROPE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 114
TABLE 38 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 114
TABLE 39 EUROPE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 115
TABLE 40 GERMANY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116
TABLE 41 GERMANY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 116
TABLE 42 GERMANY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 116
TABLE 43 GERMANY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 116
TABLE 44 GERMANY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 117
TABLE 45 GERMANY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 117
TABLE 46 GERMANY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 117
TABLE 47 U.K. NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118
TABLE 48 U.K. NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 118
TABLE 49 U.K. NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 118
TABLE 50 U.K. NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 118
TABLE 51 U.K. NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 119
TABLE 52 U.K. NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 119
TABLE 53 U.K. NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 119
TABLE 54 FRANCE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 120
TABLE 55 FRANCE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 120
TABLE 56 FRANCE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 120
TABLE 57 FRANCE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 120
TABLE 58 FRANCE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 121
TABLE 59 FRANCE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 121
TABLE 60 FRANCE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 121
TABLE 61 ITALY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 62 ITALY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 122
TABLE 63 ITALY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 122
TABLE 64 ITALY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 122
TABLE 65 ITALY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 123
TABLE 66 ITALY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 123
TABLE 67 ITALY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 123
TABLE 68 SPAIN NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
TABLE 69 SPAIN NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 124
TABLE 70 SPAIN NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 124
TABLE 71 SPAIN NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 124
TABLE 72 SPAIN NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 125
TABLE 73 SPAIN NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 125
TABLE 74 SPAIN NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 125
TABLE 75 SWITZERLAND NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 76 SWITZERLAND NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 126
TABLE 77 SWITZERLAND NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 126
TABLE 78 SWITZERLAND NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 126
TABLE 79 SWITZERLAND NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 127
TABLE 80 SWITZERLAND NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 127
TABLE 81 SWITZERLAND NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 127
TABLE 82 NETHERLANDS NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 83 NETHERLANDS NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 128
TABLE 84 NETHERLANDS NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 128
TABLE 85 NETHERLANDS NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 128
TABLE 86 NETHERLANDS NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 129
TABLE 87 NETHERLANDS NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 129
TABLE 88 NETHERLANDS NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 129
TABLE 89 BELGIUM NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 130
TABLE 90 BELGIUM NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 130
TABLE 91 BELGIUM NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 130
TABLE 92 BELGIUM NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 130
TABLE 93 BELGIUM NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
TABLE 94 BELGIUM NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 131
TABLE 95 BELGIUM NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 131
TABLE 96 RUSSIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 97 RUSSIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 132
TABLE 98 RUSSIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 132
TABLE 99 RUSSIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 132
TABLE 100 RUSSIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 133
TABLE 101 RUSSIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 133
TABLE 102 RUSSIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 133
TABLE 103 TURKEY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 104 TURKEY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 134
TABLE 105 TURKEY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 134
TABLE 106 TURKEY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 134
TABLE 107 TURKEY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 135
TABLE 108 TURKEY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 135
TABLE 109 TURKEY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 110 REST OF EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136

LIST OF FIGURES

FIGURE 1 EUROPE NASAL SPRAY MARKET: SEGMENTATION 20
FIGURE 2 EUROPE NASAL SPRAY MARKET: DATA TRIANGULATION 23
FIGURE 3 EUROPE NASAL SPRAY MARKET: DROC ANALYSIS 24
FIGURE 4 EUROPE NASAL SPRAY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 25
FIGURE 5 EUROPE NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS 25
FIGURE 6 EUROPE NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS 27
FIGURE 7 EUROPE NASAL SPRAY MARKET: DBMR MARKET POSITION GRID 28
FIGURE 8 EUROPE NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID 29
FIGURE 9 EUROPE NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 10 EUROPE NASAL SPRAY MARKET: SEGMENTATION 34
FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE EUROPE NASAL SPRAY MARKET IN THE FORECAST PERIOD 35
FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NASAL SPRAY MARKET IN 2023 AND 2030 35
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE NASAL SPRAY MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 36
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR EUROPE NASAL SPRAY MARKET MANUFACTURERS IN THE FORECAST PERIOD 37
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE NASAL SPRAY MARKET 43
FIGURE 16 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022 53
FIGURE 17 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 54
FIGURE 18 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 54
FIGURE 19 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 55
FIGURE 20 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022 61
FIGURE 21 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION) 62
FIGURE 22 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030) 62
FIGURE 23 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE 63
FIGURE 24 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, 2022 67
FIGURE 25 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION) 68
FIGURE 26 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030) 68
FIGURE 27 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE 69
FIGURE 28 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022 75
FIGURE 29 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION) 76
FIGURE 30 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030) 76
FIGURE 31 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE 77
FIGURE 32 EUROPE NASAL SPRAY MARKET: BY APPLICATION, 2022 83
FIGURE 33 EUROPE NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 84
FIGURE 34 EUROPE NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030) 84
FIGURE 35 EUROPE NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE 85
FIGURE 36 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022 92
FIGURE 37 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION) 93
FIGURE 38 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030) 93
FIGURE 39 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE 94
FIGURE 40 EUROPE NASAL SPRAY MARKET: BY END USER, 2022 99
FIGURE 41 EUROPE NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION) 100
FIGURE 42 EUROPE NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030) 100
FIGURE 43 EUROPE NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE 101
FIGURE 44 EUROPE NASAL SPRAY MARKET: SNAPSHOT (2022) 108
FIGURE 45 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2022) 110
FIGURE 46 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030) 110
FIGURE 47 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030) 111
FIGURE 48 EUROPE NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030) 111
FIGURE 49 EUROPE NASAL SPRAY MARKET: COMPANY SHARE 2022 (%) 136